Cyclosporine (CsA) and MTX are commonly used for GVHD prophylaxis in pediatric allo-SCT. Mucositis and hepatic toxicity frequently restrict the delivery of the fourth dose of MTX. Folinic acid (FA) may ameliorate MTX toxicity. We conducted a retrospective chart review of all pediatric patients who received CsA and MTX for GVHD prophylaxis from January 2000 to July 2010. Patients treated before July 2007 (N ¼ 29) did not receive FA and those treated from July 2007 onward did receive FA (N ¼ 18) . Patients who received FA were significantly more likely to receive day þ11 MTX (odds ratio (OR) 10.42, 95% confidence interval (CI): 1.21-262.27) but there was no significant difference in Grade III-IV GVHD between the two groups (OR 1.15, 95% CI: 0.08-18.14). FA did not impact relapse-free survival (RFS) (P ¼ 0.82). Increased likelihood of receiving day þ11 MTX suggests that FA ameliorates MTX toxicity, such as severe mucositis. FA administration for MTX GVHD prophylaxis should be studied in a prospective, randomized fashion.
INTRODUCTION
As the annual number of transplants continues to increase worldwide, GVHD remains a leading cause of non-relapse mortality after allo-SCT. 1 Earliest efforts at utilizing immunosuppressive agents to reduce GVHD used single-agent therapy, with no notable decreases in acute GVHD when Cyclosporine (CsA) was compared with MTX. [2] [3] [4] After the successful combination of CsA and MTX in canine BM transplantation models, seminal trials in humans demonstrated the superiority of the combined regimen over CsA alone in reducing acute GVHD. [5] [6] [7] [8] From this first report, however, it was noted that there was a significantly increased incidence of severe oral mucositis and hyperbilirubinemia in patients receiving CsA and MTX. In addition, only 58% (25/43) of the patients received full-dose MTX due to renal impairment. 7 Administration of folinic acid (FA) after MTX decreased toxicity without increasing GVHD in canine transplantation models, and later the administration of FA with MTX appeared to reduce toxicities compared with CsA alone in humans as well. 8, 9 Consequently, several adult BMT studies have supported the reduction of regimen-related toxicity by the administration of FA rescue with CsA and MTX combination therapy. 10, 11 Despite this, FA administration after MTX has not been widely adopted in practice. An European Group for Blood and Marrow Transplantation (EBMT) survey regarding GVHD prophylaxis and treatment in 1995 revealed that 46% (37/81) gave FA after MTX. There was considerable variation, however, in the administration schedule. 12 Similarly, a survey of allo-SCT centers in Australia and New Zealand reported that 44% (8/18) of responding centers routinely administered FA after MTX. 13 Although there are no published studies examining the effects of FA rescue with CsA and MTX combination therapy in pediatric patients, the EBMT proposed a uniform pediatric GVHD prophylaxis policy in 2000 to include FA administration after MTX. 14 Concurrent with the desire to ameliorate toxicity is the recognition that the ability to deliver therapy is a key aspect of efficacy. MTX doses are often omitted owing to toxicity concerns, such as mucositis or hepatic dysfunction. 15 Accordingly, multiple studies have shown that fewer than 75% of patients receive the day þ11 dose of MTX. 16, 17 Furthermore, several studies have suggested that omission of the day þ 11 dose of MTX increases the risk of acute GVHD. 18, 19 Given the potential of FA to ameliorate toxicity and improve the delivery of all MTX doses and the lack of published studies regarding the effects of FA rescue with CsA and MTX combination therapy in pediatric patients, we conducted this retrospective study to examine the effects of FA administration after MTX on the ability to deliver intended therapy, GVHD, and RFS.
PATIENTS AND METHODS
We retrospectively reviewed the charts of all patients who underwent allo-SCT at the Medical University of South Carolina Children's Hospital from January 2000 to July 2010. A total of 48 patients had planned GVHD prophylaxis of CsA and MTX at a dose of 15 mg/m 2 intravenously (i.v.) on day 1 and 10 mg/m 2 on days 3, 6 and 11. One patient was excluded for incomplete medical records. Approval was obtained from the Medical University of South Carolina Institutional Review Board.
for patients 412 kg, or 1.1 mg/kg i.v. every 6 h for four days (total dose 17.6 mg/kg) for patients p12 kg. Targeted pharmacokinetics with a target C ss of 600-900 ng/ml were used for all patients receiving BU. When administered with BU, CY was given at 50 mg/kg once daily i.v. for 4 days (total dose 200 mg/kg). All recipients of cord blood units and all sickle cell disease patients also received equine anti-thymocyte globulin 30 mg/kg in divided doses daily for 3 days (total dose 90 mg/kg). Aplastic anemia patients received CY 50 mg/kg once daily i.v. for 4 days (total dose 200 mg/kg) and equine anti-thymocyte globulin 30 mg/kg in divided doses daily for 3 days (total dose 90 mg/kg).
GVHD prophylaxis
Per institutional guidelines, CsA was initiated at 1.5 mg/kg/dose i.v. every 12 h on day 2 and adjusted to maintain a goal serum trough concentration between 150-250 ng/mL. Patients were converted to oral CsA as tolerated. 
Evaluation of GVHD
Acute GVHD was graded according to the consensus criteria. 20 
Statistical analysis
Baseline characteristics were compared using the Fisher's exact test for proportions and Wilcoxon rank-sum test for age medians. Logistic regression was used to compute the adjusted odds ratios of receiving the fourth dose of MTX, adjusting for preparative regimen, graft source and disease status at the time of transplant. The impact of FA administration following MTX was further investigated with Kaplan-Meier survival curves and a two-tailed log rank test, at a 0.05 significance level. RFS was defined as time (months) from transplant to relapse or death.
RESULTS
A total of 48 pediatric patients received CsA and MTX GVHD prophylaxis from January 2000 to July 2010. One patient was excluded due to incomplete medical records. A total of 29 patients received no FA after MTX and 18 patients received FA after MTX. Baseline characteristics are included in Table 1 . The FA group had significantly more patients with non-malignant disease and with mismatched unrelated marrow as the graft source (P ¼ 0.041 and 0.006, respectively). In the FA group, 94% received the day þ 11 dose of MTX while only 48% received it in the non-FA group (P ¼ 0.001).
Patients in the FA group were significantly more likely to receive the day þ11 dose of MTX compared with the non-FA group with an unadjusted odds ratio of 18.21 (95% confidence interval (CI): 2.13-155.47) and an adjusted odds ratio of 10.42 (95% CI: 0.87-124.62). The risk of developing grade III or IV GVHD was not significantly different between the two groups with an unadjusted odds ratio of 1.08 (95% CI: 0.16-7.2) and an adjusted odds ratio of 1.15 (95% CI: 0.09-15.08) for the FA group compared with the non-FA group. The two groups did not differ significantly with RFS as shown in Figure 1 . Day-100 RFS was 0.93 (95% CI: 0.80-1.00) for the FA group and 0.96 (95% CI: 0.89-1.00) for the non-FA group, and 1-year RFS was 0.79 (95% CI: 0.60-1.00) for the FA group and 0.83 (95% CI: 0.69-0.99) for the non-FA group (P ¼ 0.818).
Of the 18 patients who received FA after MTX, 11 (61%) had at least one detectable MTX level 24 h after administration of a MTX dose. Four (22%) patients had 2 or more detectable MTX levels. The levels ranged from 0.02 to 0.41 mmol/L, with all but 2 levels below 0.1 mmol/L. The patient with the level of 0.41 mmol/L is the only patient in the FA group who did not receive the day þ 11 MTX dose and unfortunately died from severe veno-occlusive disease (VOD). Of the other three patients with 2 or more detectable levels, two patients have continued RFS and one patient died 8 months post transplant from relapse.
DISCUSSION
Our retrospective study is the first report to date regarding the use of FA in pediatric allo-SCT patients receiving CsA and MTX for GVHD prophylaxis. Given the distinctive aspects of pediatric allo-SCT such as the overall decreased rates of GVHD and treatment of non-malignant diseases that derive no benefit from GVHD, it is important to examine the use of FA in a pediatric population. Furthermore, the initial adult studies examining the use of FA were conducted in an era when CML, a rare disease in pediatrics, was a predominant indication for allo-SCT. We focused on the impact of FA on the ability to deliver the fourth dose of MTX, as full delivery of any intended course of treatment is a key component of efficacy. In addition, as measures such as mucositis were not uniformly graded in this retrospective study, delivery of the fourth dose of MTX served as a surrogate for toxicity. We did demonstrate that the FA group was more likely to receive the day þ 11 dose of MTX, which suggests that FA was able to ameliorate MTX toxicity. Furthermore, although we did not see a subsequent difference in grade III-IV GVHD between the two groups, the FA group had significantly more mismatched, unrelated marrow grafts. Given this difference in graft sources, the lack of a difference in grade III-IV GVHD between the groups may suggest an improvement in the rates of severe GVHD due to the ability to deliver the fourth dose of MTX, although the inherent limitations of this retrospective study must be noted. Significant issues regarding the delivery of a full course of MTX have been well-documented. Two large randomized trials comparing MTX and CsA to MTX and tacrolimus revealed that only 62-73% of patients received the full 4-dose course of MTX, a delivery rate similar to other studies. 16, 17, 19, 21 None of these studies had more than 11% of pediatric patients with little to no patients under the age of 12. A strictly pediatric study evaluating the use of tacrolimus and MTX as GVHD prophylaxis demonstrated a slightly higher rate of delivery of MTX with patients receiving a mean of 83% of the scheduled MTX doses. 22 While the results of our limited, retrospective study must be interpreted with caution, we did not demonstrate a decrease in RFS or an increase in severe GVHD for the FA group that has been mentioned as a potential concern with FA administration by some groups. A recent survey of FA use in adult and pediatric transplant centers in Australia and New Zealand reported that centers not using FA reported concerns for the possibility of increasing the risk of GVHD or lack of evidence of efficacy. 13 Currently, no randomized controlled trials have evaluated the use of FA after MTX administration in adult or pediatric allo-SCT patients, but several retrospective studies suggest a reduction of toxicity with use of FA. A retrospective study of adult-related donor SCT patients receiving FA after MTX administration demonstrated significantly lower incidences of grade II-IV stomatitis, hepatic toxicity and total parental nutrition use compared with historical controls. There was no significant difference between Grade II-IV acute GVHD, chronic GVHD or EFS. 10 A subsequent report of adult allo-SCT patients utilized FA administration 24 h after each MTX dose as well as extended administration after day þ 11 until engraftment. The authors reported no omitted doses of MTX or cases of grade III or higher mucositis and a 29% incidence of acute GVHD; however, no comparison group was used in this study.
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A more recent retrospective study of adult patients included myeloablative and reduced-intensity regimens with MTX administered only on days þ 1 (15 or 10 mg/m 2 ), 3 (7 or 10 mg/m 2 ) and 6 (7 or 10 mg/m 2 ). At the physician's discretion, FA was administered at the same dose of MTX 12, 18 and 24 h after MTX doses on days 1 and 3 and at 24, 30 and 26 h after the MTX dose on day 6 in addition to a FA mouthwash on days 1-7. Systemic FA administration significantly reduced the incidence of severe oral mucositis with no difference in the incidence of acute GVHD. 23 Without a scheduled FA rescue, a recent retrospective study analyzed the effects of daily folate intake from oral multivitamins and total parenteral nutrition solutions on days 0-18 in adult allo-SCT patients who received 4 doses of MTX. There were no differences in mucositis, acute GVHD, relapse or survival at varying levels of folic acid supplementation. 24 Notably, several studies have explored the effects of MTX pharmacogenetics on toxicity and outcome measures after allo-SCT. The first study that demonstrated a relationship between 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and transplant outcomes involved 220 adult patients who were genotyped for the MTHFR C677T polymorphism. For patients with the homozygous TT variant (lower enzyme activity), there was a significant increase in mucositis and time to platelet engraftment. 25 This same cohort was slightly expanded and underwent further analyses of an additional MTHFR polymorphism (A1298C) as well as two polymorphisms in the thymidylate synthase gene. In an analysis of combined genotypes, the MTHFR A1298C polymorphism with a wild-type MTHFR 677CC genotype showed no changes in the risk of mucositis while the MTHFR C677T genotype persisted as a risk factor for mucositis. 26 In addition, another study demonstrated that MTHFR 677CT and TT genotypes in HLA-matched related donors are associated with a decreased risk of GVHD. 27 Recently, an analysis of the impact of donor and recipient MTHFR polymorphisms demonstrated not only differential effects of MTHFR polymorphisms on outcomes but also varying effects in response to FA administration. FA administration, however, was based on the treating physician's discretion, making it difficult to reach definitive conclusions. 28 Given the randomized studies in adults demonstrating reduced mucositis when combining mycophenolate mofeteil (MMF) with CsA or tacrolimus rather than MTX, a question could be raised regarding the utility of maximizing strategies to enhance delivery of the full course of MTX. 29, 30 However, the randomized trial with tacrolimus showed that MMF was less effective than MTX at reducing the risk of severe acute GVHD. 30 Furthermore, in vitro data demonstrate that MMF has substantially greater inhibition of natural killer cell proliferation and cytotoxic function than MTX, which may lead to a significant decrease in the GVL effect of natural killer cells. 31, 32 Our study was the first to assess the use of FA for MTX-related toxicity in pediatric allo-SCT patients receiving CSA and MTX for GVHD prophylaxis. FA appears to reduce MTX-related toxicity without increasing the risk of GVHD or affecting RFS. Randomized controlled trials with analyses of donor and recipient MTHFR genotypes are needed to validate the universal use of FA supplementation in both adult and pediatric allogeneic SCT patients receiving MTX. Folinic acid after MTX in pediatric allo-SCT MP Hudspeth et al
